Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$15,269 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-221 Mln
ROE
-1.2 %
ROCE
-76.3 %
P/E Ratio
--
P/B Ratio
44.3
Industry P/E
--
EV/EBITDA
-5.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.3
Face value
--
Shares outstanding
742,665,984
CFO
$-341.32 Mln
EBITDA
$-348.02 Mln
Net Profit
$-891.55 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Summit Therapeutics - ADR
| 13.0 | -21.8 | 2.1 | 154.2 | 165.3 | 42.3 | 5.0 |
|
BSE Sensex
| 4.7 | 1.2 | 6.5 | 6.1 | 16.5 | 18.6 | 11.4 |
|
S&P Midcap 400
| -2.6 | 1.7 | 3.0 | 3.5 | 10.6 | 11.1 | 7.0 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Summit Therapeutics - ADR
| 573.1 | -38.6 | 58.0 | -42.8 | 193.8 | 39.1 | -89.5 |
|
S&P Midcap 400
| 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 | -12.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Summit Therapeutics - ADR
|
20.2 | 15,269.2 | -- | -- | -- | -- | -- | 44.3 |
| 313.0 | 40,381.2 | 2,348.1 | -269.7 | -9.0 | -365 | -- | 352.8 | |
| 52.0 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.1 | |
| 44.3 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
| 104.8 | 19,504.2 | 381.0 | -1,013.3 | -247.2 | -347.9 | -- | 190.5 | |
| 154.8 | 26,747.5 | 15,497.0 | 1,334.0 | 14.7 | 20.6 | 21.1 | 4.5 | |
| 127.1 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 5.0 | |
| 512.0 | 56,431.6 | 14,085.7 | 4,499.3 | 31.8 | 15.3 | 13.3 | 1.9 | |
| 287.0 | 13,114.7 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.6 | 1.9 | |
| 443.7 | 115,147.8 | 11,099.7 | -988.9 | -2.5 | -6.2 | -- | 6.9 |
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific... antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida. Read more
Co-CEO & Executive Chairman
Mr. Robert W. Duggan
Co-CEO & Executive Chairman
Mr. Robert W. Duggan
Headquarters
Miami, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Summit Therapeutics Inc - ADR stood at $ 419 Mln as on 31-Mar-25
The share price of Summit Therapeutics Inc - ADR is $20.16 (NASDAQ) as of 23-Jun-2025 13:37 EDT. Summit Therapeutics Inc - ADR has given a return of 165.27% in the last 3 years.
Summit Therapeutics Inc - ADR has a market capitalisation of $ 15,269 Mln as on 20-Jun-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Summit Therapeutics Inc - ADR is 44.32 times as on 20-Jun-2025, a 1489% premium to its peers’ median range of 2.79 times.
Since, TTM earnings of Summit Therapeutics Inc - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Summit Therapeutics Inc - ADR and enter the required number of quantities and click on buy to purchase the shares of Summit Therapeutics Inc - ADR.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
The CEO & director of Mr. Robert W. Duggan. is Summit Therapeutics Inc - ADR, and CFO & Sr. VP is Mr. Robert W. Duggan.
There is no promoter pledging in Summit Therapeutics Inc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
5,643
|
|
|
4,016
|
|
|
2,675
|
|
|
1,905
|
|
|
1,302
|
|
|
11,515
|
|
|
1,260
|
|
|
1,128
|
|
|
991
|
| Summit Therapeutics Inc. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Summit Therapeutics Inc - ADR was $-221 Mln.
$-0.40
(
